Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cosmos HealthFRA:V67A +23.82%27 Median PS Value is €1.67 as of Jul. 14, 2026, which is 100% below its 10-year median of 0.21. GuruFocus rates FRA:V67A with a GF Score™ of 27/100 and a GF Value™ of €0.32 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 70 Medical Distribution companies, Cosmos Health ranks better than 97.14% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Cosmos Health's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €1.722. Cosmos Health's 10-Year median PS Ratio is 0.9698. Therefore, the Median PS Value for today is €1.67.
As of today (2026-07-14), Cosmos Health's share price is €0.2734. Cosmos Health's Median PS Value is €1.67. Therefore, Cosmos Health's Price to Median PS Value for today is 0.16.
The historical rank and industry rank for Cosmos Health's Median PS Value or its related term are showing as below:
FRA:V67A'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.13 Med: 0.21 Max: 0.52
Current: 0.16
During the past 13 years, the highest Price to Median PS Value of Cosmos Health was 0.52. The lowest was 0.13. And the median was 0.21.
FRA:V67A's Price-to-Median-PS-Value is ranked better than 97.14% of 70
companies
in the Medical Distribution industry
Industry Median: 0.83
vs FRA:V67A: 0.16
Cosmos Health (FRA:V67A) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Cosmos Health's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.2734
/
1.67
=
0.16
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosmos Health Median PS Value Related Terms
Cosmos Health Median PS Value Historical Data
* Premium members only.
The historical data trend for Cosmos Health's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:V67A vs HKPD, SNYR, YI: Median PS Value Comparison
For the Medical Distribution subindustry, Cosmos Health's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmos Health Price-to-Median-PS-Value vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cosmos Health's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Cosmos Health's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.9698.
Cosmos Health's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.722.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosmos Health (FRA:V67A) has a Median PS Value of €1.67 as of Jul. 14, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Cosmos Health and its competitors. This is 695% above median its historical median of 0.21. Over the past decade, Cosmos Health's Median PS Value has ranged from 0.13 to 0.52. According to the industry distribution chart, Cosmos Health ranks #2 out of 70 companies in the Medical Distribution industry, placing it in the top 2.9%.
Is Cosmos Health's Median PS Value too high?
Cosmos Health's current Median PS Value of €1.67 is 695% above median its 10-year median of 0.21. Over the past 10 years, this metric has ranged from a low of 0.13 to a high of 0.52. Based on the distribution chart, Cosmos Health ranks #2 out of 70 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Cosmos Health has a GF Score™ of 27/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cosmos Health's Median PS Value compare to HKPD and SNYR?
According to the Medical Distribution industry distribution chart, Cosmos Health ranks #2 out of 70 companies for Median PS Value. This places Cosmos Health in the top 3% of its industry — outperforming the majority of peers. The industry median Median PS Value is 0.83. Historically, Cosmos Health's own Median PS Value has ranged from 0.13 to 0.52 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Medical Distribution company?
The median Median PS Value among Medical Distribution companies is 0.83, based on 70 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Cosmos Health and its competitors. For the Medical Distribution industry, the median Median PS Value is 0.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosmos Health's current Median PS Value is €1.67, which is 695% above median its own 10-year median of 0.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmos Health stock overvalued right now?
Based on GuruFocus' analysis, Cosmos Health (FRA:V67A) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.32, compared to a current price of €0.27 — trading 14.6% below its estimated fair value. The current Median PS Value is €1.67, which is 695% above median its 10-year median of 0.21. Cosmos Health's overall GF Score™ is 27/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Cosmos Health (FRA:V67A), the current Median PS Value is €1.67 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosmos Health (FRA:V67A) Overvalued in 2026?
Based on GuruFocus' analysis, Cosmos Health stock appears to be undervalued.
The current stock price of €0.27 is trading 14.6% below its estimated GF Value™ of €0.32.
GuruFocus considers Cosmos Health to be Modestly Undervalued.
Key valuation signals for FRA:V67A:
Median PS Value: €1.67 (695% above median its 10-year median of 0.21)
GF Value™: €0.32 vs. price of €0.27 (14.6% below fair value)
No single metric tells the full story. See the FRA:V67A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosmos Health Inc is a diversified, vertically integrated healthcare group, owner of proprietary pharmaceutical and nutraceutical brands, generics, manufacturer and distributor of healthcare products, engaged in research & development of medicines and repurposing drugs as well as operator of a telehealth platform. The company has developed its own proprietary branded nutraceutical products, named 'Sky Premium Life' and 'Mediterranation'. Its product portfolio includes generics and over-the-counter pharmaceutical products, medicines, as well as nutraceuticals and biocides. The company's Reportable segments are Wholesale, Pharma manufacturing, and Nutraceutical and pharmaceuticals, with the majority of revenue generated from the Wholesale segment.
27GF Score
Get the complete analysis for FRA:V67A
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:V67A has been successfully added to your 
